When Genes Are Silenced, Ovarian Cancer Advances
12/15/2010
There are many mechanisms that alter the activity of genes - direct changes to the DNA code like mutations and deletions, or changes that control when genes are switched on and off, called epigenetic means. Tumor-suppressor genes are often inactivated through epigenetics, which provides an opening for the cancerous growth of cells...
Biological Diversity Of Ovarian Cancer Lessens Value Of Screening
12/15/2010
Cancer prevention experts have long been frustrated by the lack of a meaningful way to screen women for ovarian cancer. It is a relatively rare disease that often progresses with few symptoms until it is too late for potentially curative treatments, and elevated values of the most commonly used biomarker used in screening, CA125, are also related to other disorders...
Ovarian Cancer Screening Saves Few Lives
12/14/2010
The best currently available screening tests can only slightly reduce ovarian cancer deaths. That is the conclusion of new research published early online in CANCER, a peer-reviewed journal of the American Cancer Society...
Ovarian Cancer Clue: Methylation-Mediated Suppression Of A Key Pathway Is Found
12/14/2010
Ovarian cancer is the leading cause of death among gynecological cancers. To better understand the disease and improve therapies, researchers are investigating how deregulation of genes across the genome could be contributing to malignancy...
Platinum And Blue Light Combine To Combat Cancer
12/11/2010
When it comes to health care, blue lights are usually most useful on the top of ambulances; but now new research led by the University of Warwick has found a way to use blue light to activate what could be a highly potent platinum-based cancer treatment...
Latest Women's Health Report Card Reveals Setbacks
12/10/2010
A women's health report card issued Tuesday gave the U.S. an overall rating of "unsatisfactory" and issued failing grades on many specific public health goals, such as improving cervical cancer screenings, the New York Times reports. The report card -- issued by the National Women's Law Center and Oregon Health and Science University -- is the fifth since 2000...
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that projected improvements in recurrence-free survival and an only modest increase in risk due to population aging will limit growth of new drug-treatment opportunities for advanced ovarian cancer...
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard of care for first- and second-line treatment of platinum-sensitive ovarian cancer, pegylated liposomal doxorubicin (PLD)/carboplatin will replace paclitaxel/carboplatin as the standard ...
FDA Accepts Guided Therapeutics' Non-Invasive Cervical Cancer Scanner PMA Application For Review
12/06/2010
Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP) announced that it was notified by the U.S. Food and Drug Administration (FDA) that the company's premarket approval application (PMA) for the LightTouch™ Cervical Scanner, for patients at risk for cervical cancer, is "suitable for filing...
Grant Launches Cervical Cancer-Free Indiana Initiative
12/03/2010
Indiana will join a multi-state program focused on cervical cancer prevention thanks to an unrestricted gift from GlaxoSmithKline Pharmaceuticals to the Indiana University School of Medicine, in partnership with the Kristen Forbes EVE Foundation...